A carregar...
ERBB2 Emerges as a New Target for Colorectal Cancer
ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.
Na minha lista:
| Publicado no: | Cancer Discov |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4527096/ https://ncbi.nlm.nih.gov/pubmed/26243861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-0730 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|